Hypomagnesaemia in patients with metastatic colorectal carcinoma treated with cetuximab

Hepato-Gastroenterology

Volumn 59, Issue 114, 2012, Pages 366-371

  Melichar, Bohuslav ^a,c   Králíčková, Pavlína ^b   Hyšpler, Radomír ^b   Kalábová, Hana ^b   German, Jaroslav ^b   Holečková, Petra ^b   Študentová, Hana ^a   Malířová, Eva ^b  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Albumin; Calcium; Cetuximab; Colorectal carcinoma; Magnesium; Potassium

Indexed keywords

ALBUMIN; CALCIUM; CETUXIMAB; CREATININE; MAGNESIUM; POTASSIUM;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; FEMALE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POST TREATMENT SURVIVAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT;

EID: 84860595797     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10330     Document Type: Article

References (22)

1. Cunningham D, Hurnblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345. (Pubitemid 38944402)
2. Bokemeyer C, Bondarenko I, Makhson A, et al.: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27:663-671.
3. Van Cutsem E, Kohne CH, Hitre E, et al.: Cetuximab and chemotherapy as initial treatment for metastatic colrectal cancer. N Engl J Med 2009; 360:1408-1417.
4. Segaert S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16:1425-1433. (Pubitemid 41222414)
5. Segaert S, Tabernero J, Chosidow O, et al.: Management of skin reaction in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005; 3:599-606. (Pubitemid 41647826)
6. Melichar B, Cerman I, Malírová E: Successful management of infusion reaction accompanying the start of cetuximab therapy. Support Care Cancer 2007; 15:445-449. (Pubitemid 46697013)
7. Schrag D, Chung KY, Flombaum C, Saltz L: Cetuximab therapy and symptomatic hypomagnesaemia. J Natl Cancer Inst 2005; 97:1221-1224.
8. Fakih MG, Wilding G, Lombardo I: Cetuximab-induced hypomagnesaemia in patients with colorectal cancer. Clin Colorectal Cancer 2006; 6:152-156. (Pubitemid 44445751)
9. Tejpar S, Piessevaux H, Claes K, et al.: Magnesium wasting associated with epidermal growth factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007; 5:387-394. (Pubitemid 46621761)
10. Vincenzi B, Santini D, Galluzzo S, et al.: Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin Cancer Res 2008; 14:4219-4224.
11. Payne RB, Carver ME, Morgan DB: Interpretation of serum total calcium: effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J Clin Pathol 1979; 32:56-60. (Pubitemid 9108607)
12. Melichar B, Nemcová I: Eye complications of cetuximab therapy. Eur J Cancer Care 2007; 16:439-443.
13. Simpson WG, Heys SD, Whiting PH, Eremin O, Broom J: Acute phase proteins and recombinant IL-2 therapy, prediction of response and survival in patients with colorectal cancer. Clin Exp Immunol 1995; 99:143-147.
14. Bonner JA, Harari PM, Giralt J, et al.: Radiotherapy plus cetuximab for squamous-cel! carcinoma of the head and neck N Engl J Med 2006; 354:567-578. (Pubitemid 43209104)
15. Van Cutsem E, Peeters M, Siena S, et al.: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658-1664. (Pubitemid 46797944)
16. Tiel Groenestege WM, Thebault S, Van der Wijst J, et al.: Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesaemia. J Clin Invest 2007; 117:2260-2267. (Pubitemid 47219571)
17. Agus ZS: Hypomagnesaemia. J Am Soc Nephrol 1999; 10:1616-1622.
18. Elisaf M, Milionis H, Siamopoulos K: Hypomagnesemic hypokalemia and hypocalcaemia: clinical and laboratory characteristics. Miner Electrolyte Metab 1997; 23:105-112. (Pubitemid 27294737)
19. Hodgkinson E, Neville-Webbe HL, Coleman RE: Magnesium depletion in patients receiving cisplatin-based chemotherapy. Clin Oncol 2006; 18:710-718. (Pubitemid 44464042)
20. Lajer H, Daugaard G: Cisplatin and hypomagnesaemia. Cancer Treat Rev 1999; 25:47-58.
21. Lajer H, Kristensen M, Hansen HH, et al.: Magnesium and potassium homeostasis during cisplatin treatment Cancer Chemother Pharmacol 2005; 55:231-236. (Pubitemid 40142887)
22. Perrin C, Fabre C, Raoul JL, Boucher E: Behavioral disorders secondary to profound hypomagnesaemia in a patient given cetuximab for metastatic colorectal cancer hypomagnesaemia due to cetuximab treatment. Acta Oncol 2006; 45:1135-1136. (Pubitemid 44808503)